NRG Therapeutics

News

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG Therapeutics' oversubscribed Series B will fund first-in-human trials of a drug targeting mitochondrial dysfunction in neurodegenerative diseases.

News

Closeup of X-ray photography of human brain

NRG announces £16m Series A for IND for Parkinson’s and ALS

A £16 million Series A financing – led by Omega Funds – has been announced by the innovative neuroscience company

News

Charity backs R&D into Parkinson's drugs targeting mitochond...

The charity Parkinson’s UK has struck a £1 million partnership with NRG Therapeutics to develop drugs targeted at mitochondria that could protect cells producing dopamine, which have been d

NRG raises £50m to start trials of Parkinson's, ALS drug

NRG announces £16m Series A for IND for Parkinson’s and ALS

Charity backs R&D into Parkinson's drugs targeting mitochond...

EMA advisors say CSL's Tavneos should be pulled from sale

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks